Lindsay Fischer is the Associate Editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com

Cancer survivors who experience both frontal and occipital late alopecia following cytotoxic or endocrine therapy may derive clinical benefit with oral minoxidil, according to data from a study at Memorial Sloan Kettering Cancer Center (MSK), which were presented during the 2022 ASCO Annual Meeting.

Overall, hair and follicle densities increased by approximately 20% across all tested populations, and 74% of patients showed clinical improvement. Moreover, no patients required treatment discontinuation because of adverse events (AEs).

Alopecia is a common AE with approximately 65% of patients who undergo chemotherapy experiencing some degree of alopecia.1 Furthermore, 58% of patients with cancer report that hair loss is the most traumatic component of receiving chemotherapy, and 1 in 7 patients would consider declining chemotherapy because of fear of hair loss. 

Late alopecia was defined by investigators as the incomplete hair regrowth 6 months following the completion of endocrine therapy or from the initiation of endocrine therapy. This longer-lasting AE reportedly affects between 25% to 30% of survivors.

Scalp cooling is the only known prevention technique, and treatment options include scalp directed topical steroids, compounded topical minoxidil finasteride, intralesional steroids, or systematic oral low dose minoxidil. Oral minoxidil at a dose of 10 to 100 mg daily is currently FDA approved as an antihypertensive agent, but it has been used in low doses off label to treat alopecia at a dosage of 0.25 to 5 mg daily.

Investigators at MSK assessed women with late alopecia who received oral minoxidil at a dose of 1.25 mg daily between January 2018 and May 2021.The efficacy of minoxidil was assessed via standardized photography, and responses were quantified via trichosocpy (HairMetrix).

Results from 42 trichoscopy assessments conducted before and after a median of 91 days (interquartile range, 136) on oral minoxidil showed that the median percentage change in hair density (hairs/cm2) was 20.4% (

= .008) in patients with frontal alopecia and 21.4% (

 = .004) in patients with occipital alopecia, respectively. Similarly, the changes in follicular density (follicles/cm2) were 22.5% (

 = .005), respectively. Hair shaft diameter between the 2 groups was –2.0% (

The literature shows that the most common AEs associated with this treatment include hypertrichosis, lightheadedness, and fluid retention. Prospective, controlled studies are still needed to validate these findings, study authors concluded.

Overall, results from this study demonstrate the importance of symptom management in survivorship care, according to experts.

“Treating late toxicities [is] the bread and butter of survivorship,” Lidia Schapira, MD, FASCO, Professor of Oncology at Stanford University with a specialization in survivorship, said in a discussion of the poster. “Patients are often left to manage these by themselves. The idea of helping patients understand, self-manage, and become better at handling toxicities, [starting] from the first day in the hospital, is a very important concept.”

The key moving forward will be expanding these efforts to populations that have less supportive resources currently available, Schapira added.

“Supportive services such as onco-dermatology and supportive dermatology are available at major cancer centers, and I absolutely am delighted to see our colleagues at Memorial Sloan Kettering continue to find solutions for some of these festering problems,” she said. “The question is how do we scale [these efforts] and how do we bring some of these advances in survivorship care to communities that are less well resourced?”

Kuo AM, Reingold RE, Ketosugbo KF, et al. Oral minoxidil for the treatment of late alopecia in cancer survivors. 

2022;40(suppl 16):12022. doi:10.1200/JCO.2022.40.16_suppl.12022

Articles

Results of a single-center study presented at the 2022 ASCO Annual Meeting showed that oral minoxidil may be effective in treating late alopecia. Moving forward, these efforts in survivorship care will need to be expanded to less resourced areas, experts said.  

Oral Minoxidil Demonstrates Efficacy in Treating Later Stage Alopecia in Cancer Survivors

Clinical gaps in febrile neutropenia care exist, according to Jeffrey Crawford, MD, a medical oncologistat Duke Cancer Center. However, biosimilars may play an interesting role in addressing those disparities.

In 2015, the FDA approved the first biosimilar to treat chemotherapy-induced neutropenia, filgrastim-sndz (Zarxio). This agent had similar safety and efficacy to the granulocyte colony-stimulating factor (G-CSF) reference agent, filgrastim (Neupogen). In February 2022, a second biosimilar, filgrastim-ayow (Releuko), was approved for the same indication with the same reference agent.

The FDA has also approved several drugs deemed to be similar to the reference agent pegfilgrastim (Neulasta). These series of approvals began with the approval of pegfilgrastim-bmez (Ziextenzo) in November 2019, followed by the approval of pegfilgrastim-apfg (Nyvepria) in June 2020, and pegfilgrastim-bmez (Fylnetra) in May 2022.

“We [now] have several biosimilars available in the US and around the world, [with the reference agents] filgrastim and pegfilgrastim” said Crawford, in a presentation on new and emerging agents on outcomes of febrile neutropenia during the 2022 Supportive Care in Cancer Annual Meeting.

“The potential impact of this is significant; [it represents] greater patient access, greater competition between the companies, and fostered innovation.”

Because biosimilars represent a more affordable option than their reference agent, a greater proportion of patients are eligible to receive these treatments, he explained. Moreover, manufacturers can take advantage of the latest technologies, which in turn, incentivizes investment in the development of new biologic products by originator companies, particularly because they receive budgetary relief.

The more companies in the business of producing biosimilars results in further cost reductions.

Notably, the concept of extrapolation is a powerful example of how biosimilars help increase accessibility, Crawford added. For example, when the FDA approved filgrastim-sndz based on data of a population of patients with breast cancer, they did not limit the approval to that indication. Based on that study population, the FDA was also able to approve filgrastim-sndz on the following indications: neutropenia with bone marrow transplant, neutropenia in the treatment of nonmyeloid malignancies, neutropenia in acute myeloid leukemia, severe chronic neutropenia, and peripheral blood progenitor cell mobilization.

“[A singular] study done in neutropenia and breast cancer treatment allowed the field—based on the biosimilar characteristics of the molecule—to extrapolate to all of the indications,” Crawford said. “That is a very important concept that reduces the cost of development.”

Crawford spotlighted trends in G-CSF following the introduction of biosimilars in the US between 2014 and 2019. He explained that findings from a cross-sectional study assessing insurance coverage of 119,129 patients treated with chemotherapy found that among those at high risk of febrile neutropenia, 75% to 83% of patients who were commercially insured, and 75% to 86% of patients who were insured with Medicare used G-CSFs. Investigators noted that this signified an overall increase in G-CSFs during this period.

Moreover, in the fourth quarter of 2019, filgrastim-sndz represented 55.6% of short-acting G-CSF use, pegfilgrastim using the on-body injector (Neulasta Onpro) represented 44.99% of long-acting G-CSF use, and pegfilgrastim biosimilars represented 29.8% of long-acting G-CSF use.

An economic analysis on biosimilar G-CSF adoption showed that in a future scenario where pegfilgrastim-bmez was used exclusively in place of pegfilgrastim, the savings could be reinvested to provide G-CSF prophylaxis (using pegfilgrastim-bmez) for at least 10% of patients who are at an intermediate risk of febrile neutropenia. This in turn, would reduce drug and administration costs, as well as reduce febrile neutropenia-related emergency visits and hospitalizations.

“The potential [for] savings [are] huge,” Crawford emphasized. “Biosimilars are going to have an impact on disparities, they are going to have an impact on utilization, impact on our practice, and [this will] expand from this area to all areas of therapeutic agents.”

Crawford J. New and emerging agents on outcomes of febrile neutropenia: addressing clinical gaps. Presented at: 2022 Supportive Care in Cancer Annual Meeting; June 23-June 25; Toronto, Ontario.

At the 2022 Supportive Care in Cancer Annual Meeting, Jeffrey Crawford, MD, highlighted the potential value of biosimilars in reducing gaps in care for the treatment of febrile neutropenia. 

Biosimilars May Reduce Disparities in Febrile Neutropenia Treatment

Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

High overall response rates and complete metabolic response (CMR) rates were observed among patients with high-risk diffuse large B-cell lymphoma (DLBCL) who received frontline treatment with subcutaneous epcoritamab and R-CHOP, according to data from arm 1 of the phase 1/2 EPCORE NHL-2 trial (NCT04663347) presented during the 2022 EHA Congress.

 Moreover, the combination was associated with a manageable safety profile.

At a median follow-up of 6.9 months (range, 0.8-14.7), the combination regimen induced an ORR of 100% among 33 patients. Moreover, the combination resulted in a CMR rate of 77% and a partial metabolic response rate of 23%.

“Epcoritamab plus R-CHOP showed encouraging responses…[and] a manageable safety profile, [and] no new safety signals were detected,” Michael Roost Clausen, MD, PhD, of Vejle Hospital, and colleagues, wrote in a poster on the data. “These updated data support further exploration of epcoritamab plus R-CHOP in [patients with] first-line DLBCL.”

Patients with DLBCL and 3 to 5 risk factors are known to have poor outcomes with standard frontline R-CHOP (rituximab [Rituxan] plus cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone); these patients have an overall survival rate of 55% at 4 years. As such, novel therapeutic approaches are needed for this population.

Epcoritamab binds to CD3 on T cells and CD20 on B cells to elicit the T-cell–mediated killing of CD20-positive, malignant B cells. When used in combination with R-CHOP, epcoritamab-mediated T-cell cytotoxicity is maintained, according to the study investigators.

Previously, data from the dose-escalation portion of the phase 1/2 EPCORE NHL-1 trial (NCT03625037) showed that epcoritamab monotherapy had an acceptable toxicity profile with strong antitumor activity in patients with heavily pretreated B-cell non-Hodgkin lymphoma.

The agent elicited an ORR of 68% (95% CI, 45%-86%) in patients with relapsed/refractory DLBCL, which included a CR rate of 45% when given at full doses ranging from 12 mg to 60 mg. When administered at 48 mg, epcoritamab produced an ORR of 88% (95% CI, 47%-100%), with a CR rate of 38%. In patients with relapsed/refractory follicular lymphoma, epcoritamab induced an ORR of 90% (95% CI, 55%-100%), with a CR rate of 50% when given at full doses of 0.76 mg to 48 mg.

Arm 1 of the open-label, multicenter EPCORE NHL-2 trial was comprised of patients with newly diagnosed, CD20-positive DLBCL, an International Prognostic Index (IPI) score of 3 or greater, an ECOG performance status of 0 to 2, measurable disease, and acceptable organ function.

The dose-escalation portion of the trial included 10 patients. Subcutaneous epcoritamab was given at 24 mg (n = 4) or 48 mg (n = 6) given weekly for cycles 1 through 4, every 3 weeks for cycles 5 and 6, and every 4 weeks for cycle 7 and on. R-CHOP was also administered in cycles 1 through 6. The primary objectives were dose-limiting toxicities, safety, and tolerability.

A total of 23 patients were included in the dose-expansion phase of the trial. Here, patients received subcutaneous epcoritamab at 48 mg every week for cycles 1 to 4, every 3 weeks for cycles 5 and 6, and every 4 weeks for cycle 7 and on, in combination with R-CHOP for cycles 1 through 6. The primary objective of this portion of the research was antitumor activity.

Among the 33 patients evaluated, the median age was 66 years (range, 19-82), 55% were male, 48% had an ECOG performance status of 1, 79% had Ann Arbor stage IV disease, 55% had an IPI score of 3, and 85% had de novo disease. The median time from diagnosis to first dose of treatment was 26 days (range, 5-70).

At a data cutoff date of March 25, 2022, 73% of the 33 patients were still receiving treatment with the combination and 18% had discontinued the regimen. Reasons for discontinuation included disease progression (6%), toxicity (3%), or another unspecified reason (9%). Three patients had completed treatment.

The median number of epcoritamab cycles initiated was 9 (range, 1-15), and the median duration of treatment was 6.3 months (range, 0.6-11.5). Fifty-two percent of patients required a dose delay of epcoritamab because of a treatment-emergent adverse effect (TEAE). Moreover, 91% of patients completed 6 cycles of R-CHOP.

Regarding safety, the most common TEAEs included anemia (grade 1/2, 33%; grade 3, 27%), neutropenia (grade 1/2, 6%; grade 3, 9%), cytokine release syndrome (grade 1/2, 48%; grade 3, 3%), nausea (grade 1/2, 45%), injection-site reaction (grade 1/2, 42%), constipation (grade 1/2, 33%; grade 3, 3%), fatigue (grade 1/2, 36%), peripheral sensory neuropathy (grade 1/2, 33%), pyrexia (grade 1/2, 33%), peripheral edema (grade 1/2, 27%), cough (grade 1/2, 21%), diarrhea (grade 1/2, 18%; grade 3, 3%), dyspnea (grade 1/2, 18%), headache (grade 1/2, 21%), and thrombocytopenia (grade 1/2, 12%; grade 3, 9%). Forty-five percent of patients experienced grade 4 neutropenia, and 3% experienced grade 4 dyspnea.

No events of tumor lysis syndrome were reported, although 1 patient experienced grade 2 immune effector cell–associated neurotoxicity syndrome, which resolved in 4 days.

Seventeen of the 33 patients experienced CRS; 27% of patients experienced a grade 1 event, 21% experienced a grade 2 event, and 3% experienced grade 3 CRS. All these cases were resolved, with a mean of 2 days to resolution (range, 1-11). No patients discontinued treatment due to CRS. Fifteen percent of these patients received tocilizumab (Actemra).

“CRS was mostly low grade, and all cases resolved, the study authors wrote. “CRS occurrence was predictable; most cases occurred following the first full dose with a median time to onset of 2 days.”

Clausen MR, Offner F, Belada D, et al. Subcutaneous epcoritamab + R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma: phase 1/2 update. Presented at: 2022 EHA Congress; June 9-12, 2022; Vienna, Austria. Abstract P1214.

Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. 

. 2021;398(10306):1157-1169. doi:10.1016/S0140-6736(21)00889-8

Data from the phase 1/2 EPCORE NHL-2 trial suggest that the combination of epcoritamab and R-CHOP is both effective and manageable in treating patients with high-risk diffuse large B-cell lymphoma.

Frontline Epcoritamab/R-CHOP Combination Induces 100% ORR in Patients With High-Risk DLBCL

Sickle cell disease (SCD) is the most common genetic disease in the United States affecting 1 in 500 African Americans.

 Unfortunately, a major challenge for patients with SCD is lack of access to specialty hematology services. Dedicated health care providers with SCD expertise are scarce, especially in low-income and rural settings.

 Patients with SCD often utilize emergency services because of a lack of specialty care in the outpatient setting which in turn leads to increased hospital admissions and readmissions all of which contribute to high treatment costs.

In the United States alone, there are over 230,000 hospital admissions related to SCD annually, 95% of which are related to vaso-occlusive pain crisis (VOC).

The estimated annual economic cost for VOC related hospital admissions is greater than 2.4 billion dollars.

 The average hospital stay for patients with VOC is 9 to 11 days.3 In addition, patients with SCD seeking pain relief are often stigmatized and measures to manage the opioid epidemic have further limited access to necessary pain relief.

Within a major academic medical center in the Southeast, inpatient hematology/oncology providers noted a trend within the SCD population presenting for treatment. These patients were often significantly underdosed, leading to extended hospital lengths of stay as well as readmissions. In response, our multidisciplinary team implemented individualized pain protocols to provide specialized hematology care and expedited pain management; subsequently decreasing hospital length of stay and improving patient quality of life.

Our institution implemented several interventions to improve care for patients with SCD admitted for VOC. We established a team of hematology nurse practitioners to care for patients presenting with uncomplicated VOC. This allowed for specialty care as well as continuity of care for patients who experience frequent VOC.

In conjunction with a specialized SCD attending physician and outpatient nurse practitioner, individualized initial pain protocols were developed for each patient seen in the outpatient setting. Individualized pain protocols were initiated upon patient presentation to the emergency department and/or upon admission to provide expedited, appropriate pain management. To ensure continuity of care between the inpatient and outpatient settings, inpatient and outpatient sickle cell teams met weekly to discuss current inpatients pain management protocols as well as follow-up appointments and disease management treatment plans.

In addition to hematology nurse practitioner led care, these patients were placed on hematology/oncology inpatient units allowing for specialized nursing care. Nursing staff’s specialty training allowed for first line nursing interventions such as heat therapy and frequent pain reassessments to be prioritized to assist with pain management. These interventions allowed for expedited, aggressive pain regimens for our patients with sickle cell and in return have decreased hospital length of stay.

Hospital length of stay for patients with VOC across the medical institution was evaluated over the past 5 years with a focus on effect of the hematology nurse practitioner inpatient teams.

Average cost of care for this population was determined by our institution to be $1300 per day. After implementation of the above interventions within the inpatient hematology nurse practitioner team, average length of stay was 3.9 to 6.6 days compared with other teams within the medical institution averaging up to 14 days length of stay. Further, these averages were less than half of national average VOC length of stay of 9 to 11 days.

Implementation of these interventions resulted in an average health care cost savings of $3900 per patient or $808,080 per year. In addition, quality of life for patients with VOC was improved as pain was treated efficiently and effectively allowing for a shorter hospitalization.

The practice protocols established by our specialty hematology nurse practitioners allowed for improved access to care and expedited pain management. As a result, patients suffering from VOC experienced improved pain control and reduced length of stay.

Utilization of specialty nurse practitioner driven teams and use of individualized pain protocols for patients admitted with VOC in other institutions could significantly improve quality of life for patients with SCD, decrease hospital length of stay, as well as health care costs associated with inpatient admissions.

Future directives should include utilizing nurse practitioner specialty practices to provide urgent pain management in the outpatient setting to mitigate inpatient admissions.

Lovett PB, Sule HP, Lopez BL. Sickle cell disease in the emergency department. 

 2017;31(6):1061-1079. doi:10.1016/j.hoc.2017.08.009

Lee L, Smith-Whitley K, Banks S, Puckrein G. Reducing health care Disparities in sickle cell disease: a review. 

. 2019;134(6):599-607. doi:10.1177/0033354919881438

Darbari DS, Sheehan VA, Ballas SK. The vaso-occlusive pain crisis in sickle cell disease: definition, pathophysiology, and management. 

. 2020;105(3):237-246. doi:10.1111/ejh.13430

Utilization of specialty nurse practitioner driven teams and use of individualized pain protocols for patients admitted with vaso-occlusive pain crisis improves quality of life for patients with sickle cell disease, and decreased hospital stay times.

Implementation of Individualized Pain Management in Vaso-occlusive Pain Crisis 

The FDA has granted lisocabtagene maraleucel (Breyanzi; liso-cel) approval as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma with primary refractory or early relapse within 12 months of frontline treatment.

The indication includes patients who have diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B and is specific to patients who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplant due to comorbidities or age.

The regulatory decision was primarily informed by findings from the phase 3 TRANSFORM study (NCT03575351), which showed that the CAR T-cell therapy demonstrated significant clinical improvement over the standard of care for the past 20 years—salvage therapy followed by high-dose chemotherapy plus autologous stem cell transplant.

The median event-free survival with liso-cel (n = 92) was 10.1 months vs 2.3 months with standard therapy (HR, 0.34; 95% CI, 0.22-0.52

 < .0001). Most patients experienced a complete response with liso-cel (66% [95% CI, 56%-76%]) compared with less than half of those who received standard therapy (39% [95% CI, 29%-50%; 

 < .0001]). Notably, the median duration of complete response was not reached (NR) among patients treated with liso-cel (95% CI, 7.9-NR).

Furthermore, patients who received liso-cel achieved a progression-free survival double that of standard therapy at 14.8 months vs. 5.7 months, respectively. (HR, 0.41; 95% CI, 0.25-0.66;

 = .0001). Most patients receiving liso-cel (97%) received treatment compared with less than half who received high-dose chemotherapy and autologous stem cell transplant (47%).

"[Liso-cel] represents a remarkable advance over a nearly 30-year standard of care, providing significantly improved efficacy with a well-established safety profile,” Manali Kamdar, MD, lead investigator of the TRANSFORM study and associate professor, clinical director of Lymphoma Services, Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, at the University of Colorado Cancer Center, remarked in a press release. “This important milestone reinforces the benefit of offering a CAR T cell therapy option to patients earlier in their treatment journey and it’s critical that we begin the work to implement this therapy into standard practice as a second-line treatment in order to help improve outcomes for more patients.”

Nurses should note that agent comes with a boxed warning for cytokine release syndrome (CRS) and neurological toxicities.


The rate of incidence of CRS in the TRASNFORM trial was 46% (n = 122), of which 4% was grade 3 or greater (n = 11). One patient died as a result of severe CRS and 2 patients had ongoing CRS at the time of death.

The median onset time was 5 days (range, 1-15). Most cases of CRS resolved (98%) and the median duration time was 5 days (range, 1-17 days), including in those who died on study.

The most common signs of CRS included fever (93%), hypotension (49%), tachycardia (39%), chills (28%), and hypoxia (21%)

 Other potential indicators of CRS include cardiac arrhythmias (including atrial fibrillation and ventricular tachycardia), cardiac arrest, cardiac failure, diffuse alveolar damage, renal insufficiency, capillary leak syndrome, hypotension, hypoxia, and hemophagocytic lymphohistiocytosis/macrophage activation syndrome.

Patients with active infection or inflammatory disorders should not receive liso-cel. For patients who develop severe or life-threatening CRS, tocilizumab (Actemra), with or without corticosteroids, is the recommended treatment. For this reason, providers should ensure that 2 doses of tociluzmab are available prior to the infusion of liso-cel.

Patients should be monitored for neurologic toxicities, which can occur concurrently with CRS, after CRS resolution, or even in the absence of CRS. Supportive care and corticosteroids are recommended as treatment.

Overall, the rate of neurological toxicity incidence was 35% (n = 95), of which 12% (n = 31) were grade 3 or greater. Three patients died as a result of neurological toxicity and 7 had ongoing toxicity at the time of death.

The median onset time was 8 days (range, 1-46). All neurologic events had an onset time within the 8 weeks following infusion. The median duration was 12 days (range, 1-87), and 85% of cases resolved.

Among patients who experienced neurologic toxicity, 82% (n = 78) also experienced CRS. In 52 patients, the toxicities overlapped.

The most frequent neurological toxicities included encephalopathy (24%), tremor (14%), aphasia (9%), delirium (7%), headache (7%), dizziness (6%), and ataxia (6%). Other serious events such as cerebral edema and seizures may also occur with liso-cel.

For the first week following infusion, patients should be monitored daily at a certified healthcare facility for signs and symptoms of these complications. Monitoring should continue for at least 4 weeks after infusion. Any signs of symptoms of CRS should result in prompt evaluation and treatment.

US FDA approves Bristol Myers Squibb’s CAR T cell therapy breyanzi for relapsed or refractory large B-cell lymphoma after one prior therapy. News release. Bristol Myers Squibb. June 24, 2022. Accessed June 24, 2022. 

US Food and Drug Administration (FDA) accepts for priority review Bristol Myers Squibb’s supplemental biologics license application for Breyanzi (lisocabtagene maraleucel) as a second-line therapy for relapsed or refractory large B-cell lymphoma. News release. Bristol Myers Squibb; February 17, 2022. Accessed June 23, 2022. 

The FDA has approved lisocabtagene maraleucel as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma. 

FDA Approves Liso-Cel for Second-Line Large B-Cell Lymphoma 

Updated data from the phase 3 BELIEVE trial revealed a sustained reduction in the need for red blood cell transfusions among patients with β-thalassemia who received treatment with luspatercept-aamt.

Luspatercept Linked With Maintained Reduction in Transfusion Dependence Among Patients With β-Thalassemia

This year’s congress showcased strategies for communicating sensitive topics, patient experiences with immunotherapy treatments, updates in the utility of
medical cannabis, and more. 

ONS Annual Congress Focuses on Increasing Nurse Comfort and Patient Understanding in Cancer Care

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, recounts key nursing considerations with targeted therapy for chronic lymphocytic leukemia, and third-line diffuse large b-cell lymphoma options.  

Zitella Weighs In On Overarching Treatment Strategies in Hematologic Malignancies

This year’s conference highlighted advances in natural killer cells, CD39 and KRAS G12C inhibitors, and CAR T-cell therapies. 

A Quick Look at the 2022 AACR Annual Meeting

The FDA approval of dabrafenib plus trametinib for BRAF V600E–mutated unresectable or metastatic solid tumors highlights a potential need for routine BRAF testing in clinical practice, experts say.  

FDA Grants Accelerated Approval to Dabrafenib Plus Trametinib for BRAF V600E–Mutated Solid Tumors

Heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia maintained response with tisagenlecelucel according to long-term follow-up data from the phase 2 ELIANA trial. 

Pediatric/Young Adult Patients With B-ALL Continue to Derive Benefit From Tisagenlecluecel at 5-Year Follow-Up

Dr. Jackson is a certified oncology and bone marrow transplant clinical nurse specialist with clinical expertise in hematology/stem cell transplantation/cellular therapy. She is currently unit director–providing oversight of the clinical and fiscal operations of an inpatient hematology unit. Dr. Jackson is also a member of the National Association of Clinical Nurse Specialist, American Asociation of California Nurse Leaders, and the Oncology Nurses Society.

Approximately 140 in 100,000 pregnant women receive a cancer diagnosis. Of these diagnoses, 0.1% are considered malignant tumors.

Caring for a Pregnant Patient With Cancer

The intracranial objective response rate was 32% among patients with KRAS G12C–mutant, non–small cell lung cancer who received adagrasib.

Adagrasib Demonstrates CNS Activity in KRAS G12C+ NSCLC

Phase 2 findings found that patients with chemotherapy-induced anemia experienced increases in hemoglobin following treatment with roxadustat. 

Roxadustat Increases Hemoglobin Counts in Patients With Chemotherapy-Induced Anemia

Videos

Aliènne Salleroli, MS, BSN, RN, OCN, underscores the importance of open dialogue surrounding diversity, equity, and inclusion in oncology leadership. 

Aliènne Salleroli on Starting the DEI Conversation in Oncology Nursing

A Michigan State University investigator is preparing to expand on an encouraging pilot study that used a music-listening intervention to influence chemotherapy-induced nausea.

Prescribing 20 mg of Mozart for Chemotherapy-Induced Nausea

Daratumumab plus lenalidomide and dexamethasone bested standard therapy in producing rapid, deep, and durable responses across subgroups of patients with newly diagnosed multiple myeloma. 

DRd Outperforms Rd in Newly Diagnosed Multiple Myeloma 

Phase 3 findings showed that panitumumab plus mFOLFOX significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer.

Frontline Panitumumab/mFOLFOX Elicits Longest Overall Survival To-Date in RAS Wild-Type Metastatic CRC

Regardless of other identified driver genomic alterations, patients with heavily pretreated, advanced, non–small cell lung cancer achieved encouraging responses with patritumab deruxtecan.

Patritumab Deruxtecan Produces Early Responses in Advanced NSCLC Regardless of Variant Genomic Alterations

A study analyzing the long-term adrenal insufficiency outcomes of patients receiving immune checkpoint inhibition therapy found that secondary insufficiency was more common than primary in this patient population. 

Top Medical News

Oral Minoxidil Demonstrates Efficacy in Treating Later Stage Alopecia in Cancer Survivors

Biosimilars May Reduce Disparities in Febrile Neutropenia Treatment

Frontline Epcoritamab/R-CHOP Combination Induces 100% ORR in Patients With High-Risk DLBCL

Implementation of Individualized Pain Management in Vaso-occlusive Pain Crisis

FDA Approves Liso-Cel for Second-Line Large B-Cell Lymphoma

Most Recent